Chunsheng Li
Research Subjects
Research Interests
Chunsheng Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Bo Zhang
The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
1 shared publicationRan Xia
The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
1 shared publicationXinxin Wang
The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
1 shared publication
Latest Publications
- Open Access
- 15 May 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (5)
Gut microbiota in coronary artery disease: a friend or foe?
There is growing interest in the role of gut microbiota in the pathophysiology of several diseases, including coronary artery diseases (CAD). Gut microorganisms may produce beneficial effects in myocardial ischemia either directly in the form of exogenous administration or indirectly by acting on fiber-rich food to produce important cardioprotective components. The harmful effects of gut microbiota in CAD are due to alteration in their composition with a significant decrease in Bacteroidetes and an increase in Firmicutes, Escherichia, Shigella, and Enterococcus. The altered microbiota may produce potentially toxic metabolites, including trimethylamine-N-oxide (TMAO). Indeed, the fasting plasma levels of TMAO are directly correlated to increased risk of major cardiovascular events in CAD patients, and it is proposed as a potential biomarker to predict the onset of major cardiovascular events. It is concluded that the change in the composition of gut microbiota in CAD patients may predispose to more harmful effects. However, exogenous delivery of probiotics may overcome the detrimental effects of myocardial ischemia.
- 15 May 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (5)
Open AccessGut microbiota in coronary artery disease: a friend or foe?
There is growing interest in the role of gut microbiota in the pathophysiology of several diseases, including coronary artery diseases (CAD). Gut microorganisms may produce beneficial effects in myocardial ischemia either directly in the form of exogenous administration or indirectly by acting on fiber-rich food to produce important cardioprotective components. The harmful effects of gut microbiota in CAD are due to alteration in their composition with a significant decrease in Bacteroidetes and an increase in Firmicutes, Escherichia, Shigella, and Enterococcus. The altered microbiota may produce potentially toxic metabolites, including trimethylamine-N-oxide (TMAO). Indeed, the fasting plasma levels of TMAO are directly correlated to increased risk of major cardiovascular events in CAD patients, and it is proposed as a potential biomarker to predict the onset of major cardiovascular events. It is concluded that the change in the composition of gut microbiota in CAD patients may predispose to more harmful effects. However, exogenous delivery of probiotics may overcome the detrimental effects of myocardial ischemia.